Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept

Carolyn I Rodriguez¹, Jordana Zwerling¹, Eyal Kalanthroff¹+6

• ¹From the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.